FOXO4-DRI
FOXO4-DRI (D-Retro-Inverso) is the vanguard of experimental senolytic therapy—a highly advanced, heavily engineered peptide designed exclusively to hunt down and obliterate "zombie" (senescent) cells. As tissues age or suffer severe oxidative stress, damaged cells refuse to die, instead secreting Senescence-Associated Secretory Phenotypes (SASP) that trigger massive systemic inflammation and aging. FOXO4-DRI selectively forces these toxic, age-causing cells to commit cellular suicide, dramatically reducing frailty, reversing organ dysfunction, and clearing the biochemical markers of advanced aging.
Quick Stats
Scientific Data
Mechanism of Action
FOXO4-DRI is a D-retro-inverso (DRI) peptide that selectively induces apoptosis (programmed cell death) in senescent cells while leaving healthy cells unharmed. It is the first rationally designed peptide-based senolytic.
In senescent cells, the FOXO4 transcription factor binds and sequesters p53 in the cytoplasm, preventing p53 from entering the nucleus and triggering apoptosis. Senescent cells are otherwise resistant to normal cell death despite accumulating DNA damage. FOXO4-DRI competes with endogenous FOXO4 for p53 binding, freeing p53 to translocate to the nucleus and activate apoptotic gene programs. The D-retro-inverso (mirror amino acid) design makes it resistant to protease degradation, enabling systemic activity.
In mouse studies, FOXO4-DRI reversed aging phenotypes including fur loss/discoloration, renal dysfunction, and physical frailty. Liver senescent cell burden was reduced significantly after just 3 doses. This is a landmark proof-of-concept for senolytic peptide therapy.
Source: PMID: 28340339
Background & History
FOXO4-DRI is a D-amino acid retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 inside senescent cells. Developed by Peter de Keizer at the Princess Máxima Center (Netherlands), it was published in Cell (2017) showing it selectively induced apoptosis in senescent cells — the first demonstration that targeted senolysis with a peptide was achievable. This landmark paper established FOXO4-DRI as a potentially transformative longevity compound. It specifically kills senescent cells (which drive aging via SASP) while leaving normal cells unaffected.
Research Use Cases
- ✓Cellular senescence clearance (senolytics) for longevity
- ✓Cancer treatment-induced accelerated aging reversal
- ✓Age-related pathology from SASP (senescence-associated secretory phenotype)
- ✓Frailty and physical decline associated with senescent cell burden
Dosing Protocol
| Typical Dose | 5-20 mg/kg body weight |
| Frequency | Every 3 days × 3 doses (protocol) |
| Half-Life | ~2-6 hours (estimated) |
| Common Vial Sizes | 10 mg, 50 mg |
Dosing Protocols
Mouse-Derived Protocol (Human Translation)
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 5000–20000 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 3857 mcg | 9643 mcg | 15429 mcg |
| 140 lb(63 kg) | 4500 mcg | 11250 mcg | 18000 mcg |
| 160 lb(73 kg) | 5214 mcg | 13036 mcg | 20857 mcg |
| 180 lb(82 kg) | 5857 mcg | 14643 mcg | 23429 mcg |
| 200 lb(91 kg) | 6500 mcg | 16250 mcg | 26000 mcg |
| 220 lb(100 kg) | 7143 mcg | 17857 mcg | 28571 mcg |
| 250 lb(113 kg) | 8071 mcg | 20179 mcg | 32286 mcg |
💉 For exact syringe units based on your vial concentration, use the FOXO4-DRI Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Senolytic / Cellular Rejuvenation
LowMost targeted senolytic peptide known. Proof-of-concept in mice is compelling, but human data is very limited.
Longevity Research
LowRepresents a new class of aging intervention. Suitable only for experimental longevity research use.
Reconstitution Example
Safety & Considerations
Research peptide with very limited human data. Initial mouse studies are promising but not equivalent to human safety data. May cause transient inflammation as senescent cells are cleared. Not recommended for cancer patients. Very expensive custom synthesis. Completely experimental — use only under physician supervision.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Experimental compound — very limited human data. Induces apoptosis specifically in p21-positive senescent cells. Theoretical concern: some senescent cells serve protective roles (wound healing senescence, placental cells) — unknown impact with repeated dosing. Use infrequently (quarterly cycles per de Keizer protocol).
Synergies & Common Stacks
FOXO4-DRI clears existing senescent cells; Epitalon activates telomerase to prevent cells from becoming senescent via telomere erosion. Sequential senolytic + senomorphic protocol.
FOXO4-DRI removes senescent cells; NAD+ supports the healthy cells that replace them through SIRT1 and DNA repair mechanisms.
Dosing Quick Reference
Frequently Asked Questions
How does FOXO4-DRI kill senescent cells?▼
What is the FOXO4-DRI protocol?▼
References
- Baar MP, Brandt RMC, Putavet DA, Klein JDD, de Keizer PLJ et al. “"Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis".” Cell (2017). PMID: 28340339
📚 Related Articles
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code